|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.80 USD | +2.33% |
|
+8.72% | -19.71% |
| Apr. 13 | Jefferies Initiates Veracyte at Buy With $45 Price Target | MT |
| Mar. 16 | Veracyte names Kevin Haas as chief development and technology officer | RE |
Company Valuation: Veracyte, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,927 | 1,703 | 2,009 | 3,069 | 3,328 | 2,686 | - | - |
| Change | - | -41.83% | 18.01% | 52.74% | 8.44% | -19.3% | - | - |
| Enterprise Value (EV) 1 | 2,755 | 1,524 | 1,793 | 2,828 | 2,915 | 2,163 | 2,019 | 1,851 |
| Change | - | -44.69% | 17.65% | 57.76% | 3.07% | -25.82% | -6.62% | -8.33% |
| P/E ratio | -37.1x | -46.5x | -27x | 128x | 51.3x | 37.1x | 31.1x | 31.1x |
| PBR | 2.67x | 1.59x | 1.93x | 2.63x | 2.55x | 1.87x | 1.71x | 1.56x |
| PEG | - | 0.9x | -0x | -1x | 0x | 3.4x | 1.6x | -719.36x |
| Capitalization / Revenue | 13.3x | 5.74x | 5.57x | 6.88x | 6.44x | 4.66x | 4.15x | 3.77x |
| EV / Revenue | 12.6x | 5.14x | 4.97x | 6.34x | 5.64x | 3.75x | 3.12x | 2.6x |
| EV / EBITDA | -44.2x | -101x | -30.6x | 30.8x | 20.5x | 14.9x | 12.1x | 10x |
| EV / EBIT | -33.6x | -37.1x | -20.9x | 175x | 50.5x | 28x | 20.9x | 17.5x |
| EV / FCF | -74.5x | -1,503x | 52.3x | 44.3x | 23x | 18.2x | 15.8x | 11.3x |
| FCF Yield | -1.34% | -0.07% | 1.91% | 2.26% | 4.34% | 5.5% | 6.32% | 8.88% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.11 | -0.51 | -1.02 | 0.31 | 0.82 | 0.91 | 1.087 | 1.087 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 219.5 | 296.5 | 361.1 | 445.8 | 517.1 | 576.5 | 647.8 | 713 |
| EBITDA 1 | -62.31 | -15.15 | -58.61 | 91.89 | 142.5 | 145.2 | 166.6 | 184.3 |
| EBIT 1 | -81.9 | -41.08 | -85.8 | 16.14 | 57.78 | 77.21 | 96.73 | 105.5 |
| Net income 1 | -75.56 | -36.56 | -74.4 | 24.14 | 66.35 | 75.05 | 92.34 | 96.23 |
| Net Debt 1 | -172.1 | -178.9 | -216.5 | -240.6 | -412.9 | -523.2 | -666.3 | -834.4 |
| Reference price 2 | 41.20 | 23.73 | 27.51 | 39.60 | 42.10 | 33.80 | 33.80 | 33.80 |
| Nbr of stocks (in thousands) | 71,043 | 71,753 | 73,040 | 77,500 | 79,049 | 79,458 | - | - |
| Announcement Date | 2/28/22 | 2/22/23 | 2/22/24 | 2/24/25 | 2/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 37.14x | 3.75x | 14.89x | -.--% | 2.69B | |
| -29.82x | 7.48x | 898.5x | -.--% | 2.23B | |
| -7.74x | 3.8x | -7.64x | -.--% | 1.59B | |
| -1224x | - | - | - | 1.1B | |
| 24.51x | 1.8x | 7.42x | 2.92% | 863M | |
| -10.04x | 2.46x | 27.65x | -.--% | 496M | |
| Average | -201.66x | 3.86x | 188.16x | 0.58% | 1.49B | |
| Weighted average by Cap. | -145.71x | 4.52x | 260.69x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- VCYT Stock
- Valuation Veracyte, Inc.
Select your edition
All financial news and data tailored to specific country editions
